Health Care Equipment & Services

GMED insider buys 25,000 shares at $53.27 amid a 3.12% weekly gain, showing strong confidence in spine‑fusion growth and future upside.

Insider sale by Centene’s chief counsel shows routine share liquidations, not a red flag. Learn what it means for investors and the company’s outlook.

SeaStar Medical: CFO buys 750 shares amid 60% decline—an insider hint of value, but with weak earnings and high volatility. Consider the risk‑reward.

Castle Biosciences insider sale: CEO’s 1,730 shares sold under Rule 10b5‑1 amid a 60% YTD price jump and earnings beat—insightful look at liquidity, strategy, and investor signals.

Insider buying at ACLARION INC signals leadership’s confidence amid market volatility – insiders buy at discounts, hinting at a future rebound and AI‑driven diagnostics upside.

Trigg Leslie’s sell‑to‑cover of 3,437 Outset Medical shares is a routine tax‑cover move, not a bearish signal—CEO still holds strong long‑term stake while the company advances FDA‑cleared dialysis tech.

Insider sell‑to‑cover: John Brottem sells 2,632 shares of Outset Medical, reflecting routine RSU tax‑withholding and continued executive confidence.

CEO Farquhar John C.M. sells 15,560 Heartflow shares at $39.06—insider trading, market impact, and what it means for investors.

Insider buying surge at Xtant Medical Holdings signals management confidence amid a $42.8 M cap, volatile price, and upcoming regulatory milestones.

Guardant Health’s liquid‑tumor DNA platform (Guardant360 & Reveal) delivers early cancer detection, real‑time therapy guidance, and safe, non‑invasive monitoring—backed by FDA clearances and robust clinical data.